China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a Phase I/IIa clinical study for its in-house developed JAB-24114, a glutaminase enzyme (GUE) inhibitor. This marks a significant step forward in the development of innovative cancer therapies.
Mechanism of Action and Potential
Tumors are highly dependent on glutamine for growth, which can be converted into various metabolites by different GUEs. These enzymes participate in multiple pathways, including energy metabolism, nucleotide synthesis, purine synthesis, and amino acid synthesis, to support tumor growth. JAB-24114 is designed to extensively inhibit GUE, blocking multiple glutamine metabolic pathways and effectively killing tumors. Compared to similar products, JAB-24114 offers a wider treatment window.
Preclinical Results and Market Context
Preclinical in vivo studies have demonstrated that JAB-24114 can effectively inhibit tumor growth in various animal models. Currently, there are no GUE inhibitors approved for marketing worldwide, highlighting the potential of JAB-24114 to address an unmet medical need in cancer treatment.-Fineline Info & Tech
